Stanford Scientists First To Identify New Cellular Correlates of Protection Against Influenza for an Oral Flu Vaccine Developed by Vaxart

Results of the Phase II study were the first to show that VXA-A1.1 offered greater protection against viral shedding than the injected IIV.